header
NEWS ARCHIVES

Dr. Anthony Tolcher to Speak at the AACR Annual Meeting on Chemokine Therapeutic's Lead Drug

START chosen to test drug compound that suppresses cancer-causing gene

Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic

START appoints new director of preclinical research

South Texas Accelerated Research Therapeutics Gains Highly Respected Cancer Drug Researcher Michael Wick, Ph.D.

START co-founder accepts position at
Johnson & Johnson

START chosen to test drug compound that suppresses cancer-causing gene

Dr. Anthony Tolcher to Speak at the AACR Annual Meeting on Chemokine Therapeutic's Lead Drug

Cyclacel Pharmaceuticals Presents Insights into the Mechanisms of Its Cell Cycle Inhibitor Drugs

START gains more recognition in cancer-fighting effort


Jobs in Cancer Medicine

Local Cancer Researcher Sees Benefit from Network Effort

Calando Pharmaceuticals Doses First Patient in siRNA Phase I Clinical Trial

Proteolix Tries Carfilzomib For Relapsed Solid Tumors

Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO

ImmunoGen, Inc. Announces Start of IMGN388 Clinical Testing
4319 Medical Drive, Suite 205
San Antonio, TX 78229
   Phone: (210) 593-5250
Fax: (210) 615-1121 		 
Directions